ClinicalTrials.gg
Active, not recruitingNCT03920007Updated Aug 3, 2026Results posted

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

A Phase 1/2 interventional study of ATSN-101 and ATSN-101 Diluent Solution in Leber Congenital Amaurosis, LCA and LCA1, sponsored by Atsena Therapeutics Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Atsena Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Leber Congenital Amaurosis with a site in United States — 4 open to participants now, 9 under way, 3 of them phase 3. Leber Congenital Amaurosis · United States.

Enrollment
9th of 16
15 · median 18
Started
2019
with 4 others
Phase 1/2
9 of 23
1 open now
Registered
19th of 23
by date
Lead sponsor
1 of 23
Atsena Therapeutics Inc.

Among the 23 studies in Leber Congenital Amaurosis with a site in United States, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2019, is one of 9 in phase 1/2, and was the 19th registered.

Leber Congenital Amaurosis

32 studies on the registry are indexed under Leber Congenital Amaurosis; 4 are open to participants now.

Browse Leber Congenital Amaurosis studies →

Open to participants now

4 of the 23 studies in Leber Congenital Amaurosis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Leber Congenital Amaurosis studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Leber Congenital Amaurosis with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the safety and tolerability of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA).

Secondary Objective:

To evaluate the efficacy of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with GUCY2D-LCA.

Read the detailed description

Study duration per participant is approximately 112 weeks including: an approximately 56-day screening/baseline period, an approximately 52-week study observation period including 1 treatment day, and an approximately 52-week safety follow-up period. The end of study visit will be approximately 260 weeks after the Investigational Medicinal Product (IMP) administration.

The study is separated into 2 parts including a dose escalation phase (Part A) and a dose expansion phase (Part B). In Part B participants will be treated at the maximum tolerated dose (MTD) or maximum administered dose (MAD) determined from Part A.

03

Conditions studied

  • Leber Congenital Amaurosis
  • LCA
  • LCA1

Keywords

  • GUCY2D
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant with clinical diagnosis of Leber congenital amaurosis caused by biallelic mutations in the GUCY2D (retinal guanylate cyclase) gene with all of the following: a) Documented mutations in both alleles of the GUCY2D gene per testing in a CLIA-approved laboratory, b) For Cohort 1-3, best corrected visual acuity (BCVA) of 20/200 or worse in the eye to be injected; subsequent cohorts may include BCVA of 20/80 or worse in the eye to be injected, c) Photoreceptor (outer nuclear) layer structure identifiable on an optical coherence tomography (OCT) scan across the central retina.
  • Age ≥18 years for Cohorts 1 through 4, and age ≥ 6 years and \<18 years for Cohort 5.
  • Male and female participants must follow the requirements of the trial.
  • Participants must agree to not donate blood, organs, tissues, cells or sperm for at least three months following ATSN-101 administration.

Exclusion criteria

Exclusion criteria:

  • Complicating systemic diseases (such as medical conditions causing ) that would preclude the gene transfer, ocular surgery or planned study procedures.
  • History of (HIV) infection.
  • Pre-existing eye conditions in the study eye that would preclude the planned surgery or interfere with the assessment and interpretation of study endpoints: for example, glaucoma or optic neuropathy that has resulted in significant visual loss, corneal or lenticular abnormalities or opacities that would preclude view of the fundus or performance of the outcome measures, uveitis, retinopathy and maculopathy that in the opinion of the Investigator are causing significant visual loss.
  • Presence of significant ocular abnormalities in the study eye that in the opinion of the Investigator would preclude the planned surgery, effective safety follow-up, or interfere with the interpretation of study endpoints (eg, glaucoma, corneal or significant lens abnormalities or opacities, pre-existing uveitis, intraocular infection, choroidal neovascularization).
  • Any to the planned surgical procedure, such as contraindications to the use of anaesthesia or allergy to medications planned in the peri-operative period.
  • Known allergy or to any component of the medicinal product (IMP), diagnostic agents used during the study or medications planned for use in the peri-operative period, particularly .
  • Women who are pregnant (defined as positive beta-Human Chorionic Gonadotropin (HCG) blood or urine test), lactating or breastfeeding.
  • Any ocular procedure, either planned or performed within 6 months of Day 1, which would interfere with the planned surgery or the interpretation of study endpoints in the opinion of the Principal Investigator (PI).
  • Laboratory test abnormalities or abnormalities in that in the opinion of the PI would make the participant unsuitable for participation in the study.
  • Significant intercurrent illness or infection during the 28 days prior to enrollment.
  • Current substance use disorder.
  • Use of any investigational agent administered within 5 times the elimination half-life of that investigational agent prior to ATSN-101 administration.
  • Enrollment in any other clinical treatment study, for any condition, including those relating to GUCY2D-LCA, throughout the duration of the ATSN-101 study participation.
  • Use of anticoagulation therapy within two weeks prior to surgery.
  • Use of immunosuppressive medications.
  • Current, planned during the course of this trial, or past (within 5 times the elimination half-life of that therapy prior to ATSN-101 administration) use of anti-viral therapy that would inactivate the investigational agent.
  • Received gene therapy within the last 15 years.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    ATSN-101

    ATSN-101 single dose according to an ascending dose design (dose escalation phase) or ATSN-101 single dose (dose expansion phase)

    Drug: ATSN-101 · Drug: ATSN-101 Diluent Solution · Drug: Prednisone · Drug: Triamcinalone Acetonide · Drug: 1% Prednisolone · Drug: Trimethoprim/polymyxin B

Interventions

  • DrugATSN-101

    Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection

  • DrugATSN-101 Diluent Solution

    Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection

  • Pharmaceutical form:Tablet Route of administration: Oral

  • DrugTriamcinalone Acetonide

    Pharmaceutical form:Suspension Route of administration: Peri-ocular injection

  • DrugPrednisoloneStudies of PrednisolonePrednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form:Suspension Route of administration: Drops

  • DrugTrimethoprim/polymyxin B

    Drug pages: TrimethoprimStudies of TrimethoprimTrimethoprim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Polymyxin BStudies of Polymyxin BPolymyxin B pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form:Solution Route of administration: Topical

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period

    Number of participants with treatment-emergent AEs will be summarized in each cohort (this includes cohorts 1 - 5)

    Time frame: From Baseline to Week 52

Secondary outcomes

  1. Change From Baseline of Best-Corrected Visual Acuity (BCVA) Between the Treated and Untreated Eyes

    Mean change from Baseline to Week 52 in BCVA (LogMAR) in the treated eye and untreated eye (control). In logMAR notation (logarithm of the minimum angle of resolution) is interpreted as follows: Lower LogMAR values indicates better vision. Higher LogMAR values indicates worse vision.

    Time frame: Baseline to Week 52

  2. Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Light Adapted

    Mean change from Baseline to Week 52 in sensitivity as measured by the full-field stimulus testing - Light Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.

    Time frame: Baseline to Week 52

  3. Mean Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Dark Adapted

    Mean change from Baseline to Week 52 in sensitivity as measured by the full-field stimulus testing - Dark Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.

    Time frame: Baseline to Week 52

  4. Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period

    Number of participants with treatment-emergent AEs will be summarized in each cohort (this includes cohorts 1 - 5)

    Time frame: From Baseline to Week 260

  5. Change From Baseline of Best-Corrected Visual Acuity (BCVA) Between the Treated and Untreated Eyes

    Mean change from Baseline to Week 260 in BCVA (LogMAR) in the treated eye and untreated eye (control). In logMAR notation (logarithm of the minimum angle of resolution) is interpreted as follows: Lower LogMAR values indicates better vision. Higher LogMAR values indicates worse vision.

    Time frame: Baseline to Week 260

  6. Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Light Adapted

    Mean change from Baseline to Week 260 in sensitivity as measured by the full-field stimulus testing - Light Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.

    Time frame: Baseline to Week 260

  7. Mean Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Dark Adapted

    Mean change from Baseline to Week 260 in sensitivity as measured by the full-field stimulus testing - Dark Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.

    Time frame: Baseline to Week 260

07

Results

Posted Aug 3, 2026

Participant flow

Study screening and enrollment occurred between October 2019 through May 2022. A total of 23 patients were screened, resulting in 2 enrollments at the Casey Eye Institute - Oregon Health and Science University and 13 enrollments at the Scheie Eye Institute - University of Pennsylvania to reach the study's goal of 15 enrolled patients across all cohorts.

Enrollment to Week 52
Participant flow — Enrollment to Week 52
MilestoneATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)
Started33333
Completed33333
Not completed00000
Enrollment to Week 260
Participant flow — Enrollment to Week 260
MilestoneATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)
Started33333
Completed00000
Not completed33333

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period

Number of participants with treatment-emergent AEs will be summarized in each cohort (this includes cohorts 1 - 5)

Time frame:
From Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period
ParticipantsATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)
Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period33333
SecondaryChange From Baseline of Best-Corrected Visual Acuity (BCVA) Between the Treated and Untreated Eyes

Mean change from Baseline to Week 52 in BCVA (LogMAR) in the treated eye and untreated eye (control). In logMAR notation (logarithm of the minimum angle of resolution) is interpreted as follows: Lower LogMAR values indicates better vision. Higher LogMAR values indicates worse vision.

Time frame:
Baseline to Week 52
Reported as:
Mean · LogMAR
Change From Baseline of Best-Corrected Visual Acuity (BCVA) Between the Treated and Untreated Eyes
LogMARTreated EyeUntreated Eye
ATSN-101 Cohort 1-0.27 ± 0.30-0.19 ± 0.35
ATSN-101 Cohort 2-0.08 ± 0.09-0.04 ± 0.04
ATSN-101 Cohort 3-0.37 ± 0.470.00 ± 0.00
ATSN-101 Cohort 4 (Adult Expansion)-0.12 ± 0.110.03 ± 0.03
ATSN-101 Cohort 5 (Pediatric Expansion)-0.05 ± 0.18-0.01 ± 0.02
ATSN-101 High Dose-0.16 ± 0.250.01 ± 0.03
Statistical analysis
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.42 · Mean difference (final values): -0.07
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.32 · Mean difference (final values): -0.04
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.46 · Mean difference (final values): -0.37
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.10 · Mean difference (final values): -0.15
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.77 · Mean difference (final values): -0.03
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.11 · Mean difference (final values): -0.16
SecondaryChange From Baseline of Sensitivity Between the Treated and Untreated Eye - Light Adapted

Mean change from Baseline to Week 52 in sensitivity as measured by the full-field stimulus testing - Light Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.

Time frame:
Baseline to Week 52
Reported as:
Mean · dB
Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Light Adapted
dBTreated EyeUntreated Eye
ATSN-101 Cohort 1 - Blue0.81 ± 3.09-1.11 ± 3.10
ATSN-101 Cohort 2 - Blue1.44 ± 3.103.14 ± 4.21
ATSN-101 Cohort 3 - Blue1.00 ± 0.944.83 ± 2.12
ATSN-101 Cohort 4 (Adult Expansion) - Blue-0.87 ± 6.09-1.51 ± 3.74
ATSN-101 Cohort 5 (Pediatric Expansion) - Blue5.53 ± 14.296.92 ± 10.31
ATSN-101 High Dose - Blue2.00 ± 8.843.24 ± 7.15
ATSN-101 Cohort 1 - Red2.06 ± 2.710.78 ± 2.04
ATSN-101 Cohort 2 - Red3.12 ± 5.721.71 ± 2.89
ATSN-101 Cohort 3 - Red14.20 ± 1.906.67 ± 5.66
ATSN-101 Cohort 4 (Adult Expansion) - Red2.67 ± 2.36-0.17 ± 4.01
ATSN-101 Cohort 5 (Pediatric Expansion) - Red-3.67 ± 0.470.17 ± 2.59
ATSN-101 High Dose - Red4.40 ± 8.222.22 ± 4.78
ATSN-101 Cohort 1 - White1.13 ± 2.801.67 ± 3.33
ATSN-101 Cohort 2 - White1.70 ± 2.520.90 ± 3.73
ATSN-101 Cohort 3 - White2.50 ± 1.413.00 ± 3.54
ATSN-101 Cohort 4 (Adult Expansion) - White3.10 ± 4.000.32 ± 1.74
ATSN-101 Cohort 5 (Pediatric Expansion) - White4.60 ± 13.87-2.00 ± 4.24
ATSN-101 High Dose - White3.51 ± 7.790.42 ± 3.20
Statistical analysis
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.41 · Mean difference (final values): 1.92
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.13 · Mean difference (final values): -1.70
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.14 · Mean difference (final values): -3.83
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.85 · Mean difference (final values): 0.64
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.66 · Mean difference (net): -1.39
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.43 · Mean difference (final values): -1.24
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.32 · Mean difference (final values): 1.28
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.61 · Mean difference (final values): 1.42
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.39 · Mean difference (final values): 7.53
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.25 · Mean difference (final values): 2.83
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.33 · Mean difference (final values): -3.83
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.44 · Mean difference (final values): 2.18
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.76 · Mean difference (final values): -0.53
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.51 · Mean difference (final values): 0.80
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.80 · Mean difference (final values): -0.50
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.19 · Mean difference (final values): 2.78
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.86 · Mean difference (final values): -1.25
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.68 · Mean difference (final values): 0.69
SecondaryMean Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Dark Adapted

Mean change from Baseline to Week 52 in sensitivity as measured by the full-field stimulus testing - Dark Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.

Time frame:
Baseline to Week 52
Reported as:
Mean · dB
Mean Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Dark Adapted
dBTreated EyeUntreated Eye
ATSN-101 Cohort 1 - Blue6.89 ± 6.192.78 ± 3.91
ATSN-101 Cohort 2 - Blue2.11 ± 3.34-0.78 ± 3.10
ATSN-101 Cohort 3 - Blue29.92 ± 11.67-2.49 ± 1.63
ATSN-101 Cohort 4 (Adult Expansion) - Blue25.53 ± 21.881.60 ± 6.57
ATSN-101 Cohort 5 (Pediatric Expansion) - Blue6.54 ± 5.952.59 ± 6.27
ATSN-101 High Dose - Blue21.36 ± 17.160.95 ± 5.35
ATSN-101 Cohort 1 - Red6.22 ± 6.051.33 ± 1.76
ATSN-101 Cohort 2 - Red3.33 ± 9.43-4.00 ± 3.77
ATSN-101 Cohort 3 - Red28.67 ± 14.610.17 ± 4.01
ATSN-101 Cohort 4 (Adult Expansion) - Red18.49 ± 11.162.89 ± 4.73
ATSN-101 Cohort 5 (Pediatric Expansion) - Red12.18 ± 10.97-3.69 ± 15.73
ATSN-101 High Dose - Red18.67 ± 12.13-0.26 ± 9.42
ATSN-101 Cohort 1 - White5.37 ± 7.161.22 ± 2.91
ATSN-101 Cohort 2 - White0.89 ± 5.50-0.78 ± 7.30
ATSN-101 Cohort 3 - White28.50 ± 21.21-2.00 ± 4.95
ATSN-101 Cohort 4 (Adult Expansion) - White24.94 ± 20.181.04 ± 5.13
ATSN-101 Cohort 5 (Pediatric Expansion) - White7.17 ± 6.604.20 ± 6.65
ATSN-101 High Dose - White20.88 ± 17.561.08 ± 5.16
Statistical analysis
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.09 · Mean difference (final values): 4.11
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.49 · Mean difference (final values): 2.89
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.14 · Mean difference (final values): 32.40
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.17 · Mean difference (final values): 23.93
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.02 · Mean difference (final values): 1.29
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.03 · Mean difference (final values): 19.88
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.20 · Mean difference (final values): 4.89
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.32 · Mean difference (final values): 7.33
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.16 · Mean difference (final values): 28.50
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.09 · Mean difference (final values): 15.60
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.39 · Mean difference (final values): 15.87
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.01 · Mean difference (final values): 18.93
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.29 · Mean difference (final values): 4.14
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.69 · Mean difference (final values): 1.67
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.23 · Mean difference (final values): 30.50
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.15 · Mean difference (final values): 23.90
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.01 · Mean difference (final values): 2.97
  • Treated Eye vs Untreated Eye · t-test, 2 sided · p = 0.02 · Mean difference (final values): 19.80
SecondaryNumber of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation Period

Number of participants with treatment-emergent AEs will be summarized in each cohort (this includes cohorts 1 - 5)

Time frame:
From Baseline to Week 260

Results for this outcome have not been posted.

SecondaryChange From Baseline of Best-Corrected Visual Acuity (BCVA) Between the Treated and Untreated Eyes

Mean change from Baseline to Week 260 in BCVA (LogMAR) in the treated eye and untreated eye (control). In logMAR notation (logarithm of the minimum angle of resolution) is interpreted as follows: Lower LogMAR values indicates better vision. Higher LogMAR values indicates worse vision.

Time frame:
Baseline to Week 260

Results for this outcome have not been posted.

SecondaryChange From Baseline of Sensitivity Between the Treated and Untreated Eye - Light Adapted

Mean change from Baseline to Week 260 in sensitivity as measured by the full-field stimulus testing - Light Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.

Time frame:
Baseline to Week 260

Results for this outcome have not been posted.

SecondaryMean Change From Baseline of Sensitivity Between the Treated and Untreated Eye - Dark Adapted

Mean change from Baseline to Week 260 in sensitivity as measured by the full-field stimulus testing - Dark Adapted in the treated eye and untreated eye. Full-field stimulus testing was performed for three stimulus colors - blue, red, and white.

Time frame:
Baseline to Week 260

Results for this outcome have not been posted.

Adverse events

Collected over From Baseline through Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATSN-101 Cohort 10/3 (0%)0/3 (0%)3/3 (100%)
ATSN-101 Cohort 20/3 (0%)1/3 (33.3%)3/3 (100%)
ATSN-101 Cohort 30/3 (0%)0/3 (0%)3/3 (100%)
ATSN-101 Cohort 4 (Adult Expansion)0/3 (0%)0/3 (0%)3/3 (100%)
ATSN-101 Cohort 5 (Pediatric Expansion)0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)
Macular HoleEye disorders0/31/30/30/30/3
EndopthalmitisInfections and infestations0/30/30/30/31/3
Retinal DetachmentEye disorders0/30/30/30/31/3
Most frequent other events
Showing 10 of 23
Most frequent other events
EventATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)
Conjunctival HaemorrhageEye disorders3/33/32/32/33/3
Ocular DiscomfortEye disorders3/33/32/32/32/3
Hypotony Of EyeEye disorders2/32/31/32/31/3
Retinal TearEye disorders1/30/30/30/30/3
Vitreal CellsEye disorders1/30/30/31/31/3
Ocular HypertensionEye disorders1/30/30/30/30/3
NasopharyngitisInfections and infestations0/31/31/31/31/3
Eye InflammationEye disorders0/30/31/31/30/3
Eye PainEye disorders0/30/31/30/31/3
Conjunctival HyperaemiaEye disorders0/30/31/31/31/3

Baseline characteristics

The baseline for a given parameter is defined as the last assessment for this parameter before first administration of the investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(Years)ATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)Total
Mean33.7 ± 11.0623.3 ± 7.5723.7 ± 7.3739.0 ± 32.0814.0 ± 1.7326.7 ± 16.21
Sex: Female, Male
Sex: Female, Male(Participants)ATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)Total
Female2132210
Male120115
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)Total
Race — American Indian or Alaska Native000000
Race — Asian101103
Race — Black or African American000000
Race — Native Hawaiian or Other Pacific Islander000000
Race — White2322110
Race — Not Reported000022
Race — Unknown000000
Ethnicity
Ethnicity(Participants)ATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)Total
Hispanic or Latino000022
Not Hispanic or Latino3333113
Not Reported000000
Unknown000000
Baseline Height (cm)
Baseline Height (cm)(cm)ATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)Total
Mean165.0 ± 11.27174.7 ± 7.57165.7 ± 1.15163.7 ± 8.33158.0 ± 10.15165.4 ± 9.05
Baseline Weight (kg)
Baseline Weight (kg)(kg)ATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)Total
Mean77.9 ± 26.2969.3 ± 15.6160.5 ± 11.0365.7 ± 18.3454.5 ± 1.4665.6 ± 16.32
Baseline BMI (kg/m^2)
Baseline BMI (kg/m^2)(kg/m^2)ATSN-101 Cohort 1ATSN-101 Cohort 2ATSN-101 Cohort 3ATSN-101 Cohort 4 (Adult Expansion)ATSN-101 Cohort 5 (Pediatric Expansion)Total
Mean28.0 ± 5.4422.6 ± 3.9422.0 ± 3.7024.4 ± 5.6922.1 ± 3.5023.8 ± 4.51
08

Study locations

2 sites
  • Casey Eye Institute - Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Scheie Eye Institute, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in May 2023, 42 months.

Results were first posted in Aug 2026, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2019
First posted
Apr 18, 2019
StartActual
Oct 22, 2019
Primary completionActual
May 19, 2023
CompletionEst.
May 19, 2027
Results first posted
Aug 3, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03920007
Lead sponsor
Atsena Therapeutics Inc.
Responsible party
Sponsor
First posted
Apr 18, 2019
Start date
Oct 22, 2019
Primary completion
May 19, 2023
Completion
May 19, 2027 (estimated)
Results posted
Aug 3, 2026
Last update
Aug 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion